| GK/MolTac |
plasma renin activity level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
renin activity |
male |
112 days
| 8 |
|
4.8 |
ng/ml/h |
1.9 |
5.37 |
radioimmunoassay |
0.0 |
0 |
|
|
|
102947 |
2783 |
| GK/MolTac |
heart rate |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart pumping trait |
male |
112 days
| 8 |
|
476.0 |
beats/min |
18.0 |
50.91 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102955 |
2783 |
| GK/MolTac |
diastolic blood pressure |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
arterial blood pressure trait |
male |
112 days
| 8 |
|
93.0 |
mmHg |
5.0 |
14.14 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102959 |
2783 |
| GK/MolTac |
stroke index |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
cardiac output trait |
male |
112 days
| 8 |
|
0.2 |
ul/g |
0.04 |
0.11 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102971 |
2783 |
| GK/MolTac |
blood hemoglobin level |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
122 days-129 days |
5 |
|
16.3 |
g/dl |
0.54 |
1.2 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103858 |
2864 |
| GK/MolTac |
blood hemoglobin level |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
164 days-171 days |
5 |
|
16.7 |
g/dl |
0.72 |
1.6 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103861 |
2864 |
| GK/MolTac |
hematocrit |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
122 days-129 days |
5 |
|
53.4 |
% |
1.25 |
2.8 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103870 |
2864 |
| GK/MolTac |
hematocrit |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
122 days-129 days |
7 |
|
54.1 |
% |
0.83 |
2.2 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103871 |
2864 |
| GK/MolTac |
red blood cell count |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
122 days-129 days |
7 |
|
9.4 |
x 10E6 cells/ul |
0.08 |
0.2 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103847 |
2864 |
| GK/MolTac |
red blood cell count |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
70 days-77 days |
7 |
|
7.8 |
x 10E6 cells/ul |
0.15 |
0.4 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103839 |
2864 |
| GK/MolTac |
red blood cell count |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
70 days-77 days |
6 |
|
6.6 |
x 10E6 cells/ul |
0.57 |
1.4 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103840 |
2864 |
| GK/MolTac |
preload recruitable left ventricle stroke work |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
cardiac output trait |
male |
112 days
| 8 |
|
73.0 |
mmHg |
6.0 |
16.97 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102983 |
2783 |
| GK/MolTac |
left ventricular diastolic blood pressure |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricular blood pressure trait |
male |
112 days
| 8 |
|
5.7 |
mmHg |
0.4 |
1.13 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102985 |
2783 |
| GK/MolTac |
blood glucose level |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood glucose amount |
male |
144 days
| 12 |
|
352.0 |
mg/dl |
39.0 |
135.1 |
blood glucose analysis |
0.0 |
0 |
|
|
|
103992 |
2885 |
| GK/MolTac |
blood malondialdehyde level |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood malondialdehyde amount |
male |
147 days
| 0 |
|
6.7 |
umol/l |
1.7 |
|
thiobarbituric acid assay |
0.0 |
0 |
|
|
|
104015 |
2885 |
| GK/MolTac |
blood glucose level |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 16 hours) then glucose solution (2 g/kg) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood glucose amount |
male |
122 days-129 days |
4 |
|
162.0 |
mg/dl |
14.0 |
28.0 |
oral glucose tolerance test |
0.0 |
0 |
|
|
|
103808 |
2864 |
| GK/MolTac |
plasma triglyceride level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
blood triglyceride amount |
male |
112 days
| 8 |
|
0.68 |
mmol/l |
0.12 |
0.35 |
automated plasma triglyceride analysis |
0.0 |
0 |
|
|
|
102941 |
2783 |
| GK/MolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
60 days
| 6 |
|
209.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
0 |
|
|
body weight |
106893 |
3071 |
| GK/MolTac |
food intake rate |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
eating behavior trait |
female |
60 days
| 6 |
|
16.1 |
g/d |
0.4 |
0.98 |
food intake measuring method |
0.0 |
0 |
|
|
food consumption |
106899 |
3071 |
| GK/MolTac |
blood glucose level |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
blood glucose amount |
female |
60 days
| 6 |
|
268.2 |
mg/dl |
14.4 |
35.27 |
blood glucose test strip read by optical glucometer |
0.0 |
0 |
tail vein blood |
|
fasting blood glucose, non fasting blood glucose |
106905 |
3071 |
| GK/MolTac |
serum insulin level |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
blood insulin amount |
female |
60 days
| 6 |
|
0.0 |
mg/dl |
0.0 |
0.0 |
enzyme linked immunosorbent assay |
0.0 |
0 |
|
|
fasting insulin, non fasting insulin |
106917 |
3071 |
| GK/MolTac |
both kidneys wet weight to body weight ratio |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
kidney mass |
female |
420 days
| 0 |
|
3.14 |
g/kg |
0.07 |
|
post excision weight measurement |
0.0 |
0 |
|
|
kidney weight, kidney weight to body weight ratio |
106953 |
3071 |
| GK/MolTac |
blood glucose level |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
blood glucose amount |
male |
112 days
| 0 |
|
190.8 |
mg/dl |
7.2 |
|
blood glucose test strip read by electrochemical glucometer |
0.0 |
0 |
|
|
|
108035 |
3109 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
105 days
| 8 |
|
325.4 |
g |
9.2 |
26.02 |
body weighing method |
0.0 |
0 |
|
|
|
110729 |
3183 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
105 days
| 10 |
|
335.6 |
g |
5.2 |
16.44 |
body weighing method |
0.0 |
0 |
|
|
|
110730 |
3183 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
105 days
| 9 |
|
337.3 |
g |
7.8 |
23.4 |
body weighing method |
0.0 |
0 |
|
|
|
110731 |
3183 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
112 days
| 10 |
|
352.4 |
g |
6.5 |
20.55 |
body weighing method |
0.0 |
0 |
|
|
|
110733 |
3183 |
| GK/MolTac |
blood glucose level |
control condition |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
blood glucose amount |
female |
56 days
| 10 |
|
127.8 |
mg/dl |
1.8 |
5.69 |
blood glucose analysis |
0.0 |
0 |
|
|
|
110264 |
3168 |
| GK/MolTac |
body weight |
control condition |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
56 days
| 10 |
|
191.0 |
g |
3.0 |
9.49 |
body weighing method |
0.0 |
0 |
|
|
|
110244 |
3168 |
| GK/MolTac |
hematocrit |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
70 days-77 days |
7 |
|
50.0 |
% |
1.06 |
2.8 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103863 |
2864 |
| GK/MolTac |
blood hemoglobin A1c level |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
122 days-129 days |
5 |
|
5.2 |
% |
0.1 |
0.22 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103882 |
2864 |
| GK/MolTac |
red blood cell count |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
70 days-77 days |
7 |
|
7.2 |
x 10E6 cells/ul |
0.3 |
0.8 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103841 |
2864 |
| GK/MolTac |
maximum rate of positive change in left ventricular blood pressure |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricular blood pressure trait |
male |
112 days
| 8 |
|
10429.0 |
mmHg/s |
568.0 |
1606.55 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102977 |
2783 |
| GK/MolTac |
urine norepinephrine level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
urine norepinephrine amount |
male |
112 days
| 8 |
|
2743.0 |
nmol/l |
883.0 |
2497.5 |
urine analysis |
0.0 |
0 |
|
|
|
102953 |
2783 |
| GK/MolTac |
cardiac index |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
cardiac output trait |
male |
112 days
| 8 |
|
97.0 |
ml/min/g |
21.0 |
59.4 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102967 |
2783 |
| GK/MolTac |
blood hemoglobin level |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
70 days-77 days |
7 |
|
15.8 |
g/dl |
0.34 |
0.9 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103851 |
2864 |
| GK/MolTac |
blood hemoglobin level |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
70 days-77 days |
6 |
|
13.1 |
g/dl |
1.18 |
2.9 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103852 |
2864 |
| GK/MolTac |
blood hemoglobin level |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
122 days-129 days |
7 |
|
17.0 |
g/dl |
0.19 |
0.5 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103859 |
2864 |
| GK/MolTac |
blood hemoglobin level |
sodium chloride solution (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
164 days-171 days |
7 |
|
17.9 |
g/dl |
0.15 |
0.4 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103860 |
2864 |
| GK/MolTac |
hematocrit |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
164 days-171 days |
7 |
|
57.7 |
% |
0.23 |
0.6 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103874 |
2864 |
| GK/MolTac |
blood hemoglobin A1c level |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
70 days-77 days |
7 |
|
4.8 |
% |
0.07 |
0.19 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103877 |
2864 |
| GK/MolTac |
blood hemoglobin A1c level |
sodium chloride solution (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
164 days-171 days |
7 |
|
6.89 |
% |
0.61 |
1.61 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103884 |
2864 |
| GK/MolTac |
blood hemoglobin A1c level |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
164 days-171 days |
7 |
|
5.61 |
% |
0.12 |
0.32 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103886 |
2864 |
| GK/MolTac |
blood glucose level |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 16 hours) then glucose solution (2 g/kg) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood glucose amount |
male |
122 days-129 days |
4 |
|
145.0 |
mg/dl |
7.5 |
15.0 |
oral glucose tolerance test |
0.0 |
0 |
|
|
|
103810 |
2864 |
| GK/MolTac |
Homeostatic Model Assessment of Insulin Resistance |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
(fasting glucose x fasting insulin)/22.5 |
14.2 |
null |
2.15 |
4.3 |
oral glucose tolerance test |
7200.0 |
0 |
|
|
|
103837 |
2864 |
| GK/MolTac |
blood dipeptidyl peptidase 4 activity level |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood enzyme amount |
male |
147 days
| 0 |
|
235.0 |
pmol/min |
25.0 |
|
blood enzyme activity assay |
0.0 |
0 |
|
|
|
104007 |
2885 |
| GK/MolTac |
blood dipeptidyl peptidase 4 activity level |
control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood enzyme amount |
male |
147 days
| 0 |
|
35.0 |
pmol/min |
14.0 |
|
blood enzyme activity assay |
0.0 |
0 |
|
|
|
104011 |
2885 |
| GK/MolTac |
blood malondialdehyde level |
control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood malondialdehyde amount |
male |
147 days
| 0 |
|
6.5 |
umol/l |
1.0 |
|
thiobarbituric acid assay |
0.0 |
0 |
|
|
|
104019 |
2885 |
| GK/MolTac |
blood glucose level |
control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood glucose amount |
male |
144 days
| 12 |
|
305.0 |
mg/dl |
18.0 |
62.35 |
blood glucose analysis |
0.0 |
0 |
|
|
|
103994 |
2885 |
| GK/MolTac |
plasma troponin T level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
blood protein amount |
male |
112 days
| 8 |
|
3044.0 |
pg/ml |
750.0 |
2121.32 |
electrochemiluminescence immunoassay |
0.0 |
0 |
|
|
|
102935 |
2783 |
| GK/MolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
240 days
| 11 |
|
280.0 |
g |
6.0 |
19.9 |
body weighing method |
0.0 |
0 |
|
|
body weight |
106894 |
3071 |
| GK/MolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
420 days
| 11 |
|
292.0 |
g |
6.0 |
19.9 |
body weighing method |
0.0 |
0 |
|
|
body weight |
106895 |
3071 |
| GK/MolTac |
food intake rate |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
eating behavior trait |
female |
420 days
| 11 |
|
17.2 |
g/d |
0.4 |
1.33 |
food intake measuring method |
0.0 |
0 |
|
|
food consumption |
106901 |
3071 |
| GK/MolTac |
blood glucose level |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
blood glucose amount |
female |
240 days
| 11 |
|
311.4 |
mg/dl |
14.4 |
47.76 |
blood glucose test strip read by optical glucometer |
0.0 |
0 |
|
|
fasting blood glucose, non fasting blood glucose |
106906 |
3071 |
| GK/MolTac |
both kidneys wet weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
kidney mass |
female |
420 days
| 0 |
|
0.92 |
g |
0.02 |
|
post excision weight measurement |
0.0 |
0 |
|
|
kidney weight, kidney weight to body weight ratio |
106939 |
3071 |
| GK/MolTac |
heart wet weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
heart mass |
female |
420 days
| 0 |
|
0.86 |
g |
0.02 |
|
post excision weight measurement |
0.0 |
0 |
|
|
|
106945 |
3071 |
| GK/MolTac |
hematocrit |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
122 days-129 days |
7 |
|
53.4 |
% |
1.44 |
3.8 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103869 |
2864 |
| GK/MolTac |
ejection fraction |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
cardiac output trait |
male |
112 days
| 8 |
|
66.0 |
% |
11.0 |
31.11 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102963 |
2783 |
| GK/MolTac |
stroke volume |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
cardiac output trait |
male |
112 days
| 8 |
|
65000.0 |
ml |
11000.0 |
31112.7 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102969 |
2783 |
| GK/MolTac |
systemic vascular resistance |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
arterial blood flow trait |
male |
112 days
| 8 |
|
2.49 |
mmHg/ml/min |
0.23 |
0.65 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102975 |
2783 |
| GK/MolTac |
red blood cell count |
sodium chloride solution (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
164 days-171 days |
7 |
|
9.8 |
x 10E6 cells/ul |
0.3 |
0.8 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103848 |
2864 |
| GK/MolTac |
blood hemoglobin level |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
122 days-129 days |
7 |
|
16.2 |
g/dl |
0.45 |
1.2 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103857 |
2864 |
| GK/MolTac |
blood hemoglobin level |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
164 days-171 days |
7 |
|
17.8 |
g/dl |
0.08 |
0.2 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103862 |
2864 |
| GK/MolTac |
hematocrit |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
70 days-77 days |
7 |
|
46.0 |
% |
2.0 |
5.3 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103865 |
2864 |
| GK/MolTac |
blood hemoglobin A1c level |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
122 days-129 days |
7 |
|
5.41 |
% |
0.08 |
0.22 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103881 |
2864 |
| GK/MolTac |
blood hemoglobin A1c level |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
122 days-129 days |
7 |
|
5.19 |
% |
0.08 |
0.2 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103883 |
2864 |
| GK/MolTac |
blood hemoglobin A1c level |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
164 days-171 days |
7 |
|
5.86 |
% |
0.24 |
0.64 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103885 |
2864 |
| GK/MolTac |
red blood cell count |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
122 days-129 days |
5 |
|
9.0 |
x 10E6 cells/ul |
0.22 |
0.5 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103846 |
2864 |
| GK/MolTac |
whole body insulin sensitivity index |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
10,000/√(FG x FI) x (Ḡ x Ī) |
1.27 |
null |
0.23 |
0.46 |
oral glucose tolerance test |
7200.0 |
0 |
measured at -5,15,30,45,60,90,120 min |
|
|
103830 |
2864 |
| GK/MolTac |
Homeostatic Model Assessment of Insulin Resistance |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
(fasting glucose x fasting insulin)/22.5 |
8.2 |
null |
1.35 |
2.7 |
oral glucose tolerance test |
7200.0 |
0 |
|
|
|
103838 |
2864 |
| GK/MolTac |
maximum rate of negative change in left ventricular blood pressure |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricular blood pressure trait |
male |
112 days
| 8 |
|
-12940.0 |
mmHg/s |
1112.0 |
3145.21 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102979 |
2783 |
| GK/MolTac |
time constant of left ventricular pressure decay |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricular blood pressure trait |
male |
112 days
| 8 |
|
8.15 |
ms |
0.19 |
0.54 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102981 |
2783 |
| GK/MolTac |
maximum rate of positive change in left ventricular blood pressure to left ventricular end-diastolic volume ratio |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricular blood pressure trait |
male |
112 days
| 8 |
|
104.0 |
mmHg/s/ul |
10.0 |
28.28 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102988 |
2783 |
| GK/MolTac |
blood glucose level |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood glucose amount |
male |
144 days
| 6 |
|
382.0 |
mg/dl |
69.0 |
169.01 |
blood glucose analysis |
0.0 |
0 |
|
|
|
103990 |
2885 |
| GK/MolTac |
plasma insulin level |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
|
37.96 |
mU/l |
6.5 |
13.0 |
oral glucose tolerance test |
0.0 |
0 |
|
|
|
103815 |
2864 |
| GK/MolTac |
plasma insulin level |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
|
38.22 |
mU/l |
5.2 |
10.4 |
oral glucose tolerance test |
0.0 |
0 |
|
|
|
103816 |
2864 |
| GK/MolTac |
blood insulin level |
control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood insulin amount |
male |
147 days
| 12 |
|
71.47 |
mU/l |
8.24 |
28.53 |
blood insulin analysis |
0.0 |
0 |
|
|
|
104003 |
2885 |
| GK/MolTac |
blood malondialdehyde level |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood malondialdehyde amount |
male |
147 days
| 0 |
|
6.7 |
umol/l |
1.6 |
|
thiobarbituric acid assay |
0.0 |
0 |
|
|
|
104017 |
2885 |
| GK/MolTac |
body weight |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 6 |
|
382.0 |
g |
13.0 |
31.84 |
body weighing method |
0.0 |
0 |
|
|
|
103981 |
2885 |
| GK/MolTac |
body weight |
control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 0 |
|
389.0 |
g |
7.0 |
|
body weighing method |
0.0 |
0 |
|
|
|
103985 |
2885 |
| GK/MolTac |
plasma glucose level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
blood glucose amount |
male |
112 days
| 8 |
|
223.2 |
mg/dl |
32.4 |
91.64 |
automated plasma glucose analysis |
0.0 |
0 |
|
|
|
102937 |
2783 |
| GK/MolTac |
blood glucose level |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
blood glucose amount |
female |
420 days
| 11 |
|
289.8 |
mg/dl |
10.8 |
35.82 |
blood glucose test strip read by optical glucometer |
0.0 |
0 |
|
|
fasting blood glucose, non fasting blood glucose |
106907 |
3071 |
| GK/MolTac |
serum fructosamine level |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
blood fructosamine amount |
female |
0 days
| 11 |
|
253.0 |
umol/l |
5.0 |
16.58 |
serum fructosamine analysis |
0.0 |
0 |
serum fructosamine analysis |
|
|
106955 |
3071 |
| GK/MolTac |
serum insulin level |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
blood insulin amount |
female |
240 days
| 11 |
|
0.0 |
mg/dl |
0.0 |
0.0 |
enzyme linked immunosorbent assay |
0.0 |
0 |
|
|
fasting insulin, non fasting insulin |
106918 |
3071 |
| GK/MolTac |
systolic blood pressure |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
arterial blood pressure trait |
female |
60 days
| 6 |
|
114.0 |
mmHg |
0.09 |
0.22 |
tail cuff plethysmography |
0.0 |
0 |
10 consecutive measurements |
|
|
106929 |
3071 |
| GK/MolTac |
kidney glomerulus basement membrane thickness |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
kidney glomerulus morphology trait |
female |
420 days
| 0 |
|
337.0 |
nm |
16.0 |
|
ex vivo electron microscopy with digital image analysis |
0.0 |
0 |
|
kidney basement membrane thickness |
|
106947 |
3071 |
| GK/MolTac |
kidney fractional mesangial volume |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
kidney glomerulus morphology trait |
female |
420 days
| 0 |
|
35.0 |
% |
1.7 |
|
ex vivo electron microscopy with digital image analysis |
0.0 |
0 |
|
kidney fractional mesangial volume |
|
106949 |
3071 |
| GK/MolTac |
body weight |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
body mass |
male |
154 days
| 0 |
|
419.0 |
g |
7.0 |
|
body weighing method |
0.0 |
0 |
|
|
|
108027 |
3109 |
| GK/MolTac |
heart weight |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
heart mass |
male |
154 days
| 0 |
|
1.39 |
g |
0.06 |
|
post excision weight measurement |
0.0 |
0 |
|
|
|
108029 |
3109 |
| GK/MolTac |
body weight |
control condition |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
56 days
| 9 |
|
188.0 |
g |
3.0 |
9.0 |
body weighing method |
0.0 |
0 |
|
|
|
110243 |
3168 |
| GK/MolTac |
tissue mitochondrial DNA to nuclear DNA ratio |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
tissue DNA amount |
male |
147 days
| 6 |
|
913.5 |
null |
400.9 |
982.0 |
real-time polymerase chain reaction assay |
0.0 |
0 |
|
tissue mitochondrial DNA to nuclear DNA ratio (CMO:0003889) |
|
138274 |
2885 |
| GK/MolTac |
arterial elastance |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricular blood pressure trait |
male |
112 days
| 8 |
|
1.26 |
null |
0.12 |
0.34 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102973 |
2783 |
| GK/MolTac |
cardiac output |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
cardiac output trait |
male |
112 days
| 8 |
|
32.0 |
ml/min |
6.0 |
16.97 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102965 |
2783 |
| GK/MolTac |
red blood cell count |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
122 days-129 days |
7 |
|
9.0 |
x 10E6 cells/ul |
0.26 |
0.7 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103845 |
2864 |
| GK/MolTac |
red blood cell count |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
164 days-171 days |
7 |
|
9.8 |
x 10E6 cells/ul |
0.04 |
0.1 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103850 |
2864 |
| GK/MolTac |
blood hemoglobin A1c level |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
70 days-77 days |
7 |
|
4.94 |
% |
0.09 |
0.24 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103875 |
2864 |
| GK/MolTac |
blood insulin level AUC to blood glucose level AUC ratio |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
AUC ins/glu |
0.0 |
null |
0.0 |
0.0 |
oral glucose tolerance test |
7200.0 |
0 |
measured at -5,15,30,45,60,90,120 min |
|
|
103823 |
2864 |
| GK/MolTac |
blood insulin level AUC to blood glucose level AUC ratio |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
AUC ins/glu |
0.0 |
null |
0.0 |
0.0 |
oral glucose tolerance test |
7200.0 |
0 |
measured at -5,15,30,45,60,90,120 min |
|
|
103824 |
2864 |
| GK/MolTac |
whole body insulin sensitivity index |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
10,000/√(FG x FI) x (Ḡ x Ī) |
2.04 |
null |
0.21 |
0.42 |
oral glucose tolerance test |
7200.0 |
0 |
measured at -5,15,30,45,60,90,120 min |
|
|
103831 |
2864 |
| GK/MolTac |
blood glucose level |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 16 hours) then glucose solution (2 g/kg) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood glucose amount |
male |
122 days-129 days |
4 |
|
177.0 |
mg/dl |
5.5 |
11.0 |
oral glucose tolerance test |
0.0 |
0 |
|
|
|
103809 |
2864 |
| GK/MolTac |
body weight |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 0 |
|
389.0 |
g |
7.0 |
|
body weighing method |
0.0 |
0 |
|
|
|
103983 |
2885 |
| GK/MolTac |
heart left ventricle weight to body weight ratio |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricle mass |
male |
112 days
| 8 |
|
3.41 |
mg/g |
0.17 |
0.48 |
echocardiography |
0.0 |
0 |
|
|
|
102990 |
2783 |
| GK/MolTac |
heart left ventricle end-diastolic anterior wall index |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricle anterior wall thickness |
male |
112 days
| 8 |
|
7.31 |
mm/kg |
0.22 |
0.62 |
echocardiography |
0.0 |
0 |
|
|
|
102994 |
2783 |
| GK/MolTac |
heart left ventricle end-diastolic diameter to body weight ratio |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricle diameter |
male |
112 days
| 8 |
|
15.29 |
mm/kg |
0.51 |
1.44 |
echocardiography |
0.0 |
0 |
|
|
|
102996 |
2783 |
| GK/MolTac |
plasma insulin level |
rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
|
27.3 |
mU/l |
4.16 |
8.32 |
oral glucose tolerance test |
0.0 |
0 |
|
|
|
103817 |
2864 |
| GK/MolTac |
serum insulin level |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
blood insulin amount |
female |
420 days
| 11 |
|
0.0 |
mg/dl |
0.0 |
0.0 |
enzyme linked immunosorbent assay |
0.0 |
0 |
|
|
fasting insulin, non fasting insulin |
106919 |
3071 |
| GK/MolTac |
body weight |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
body mass |
male |
112 days
| 0 |
|
351.0 |
g |
5.0 |
|
body weighing method |
0.0 |
0 |
|
|
|
108025 |
3109 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
119 days
| 8 |
|
343.0 |
g |
9.0 |
25.46 |
body weighing method |
0.0 |
0 |
|
|
|
110735 |
3183 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
119 days
| 10 |
|
350.1 |
g |
7.7 |
24.35 |
body weighing method |
0.0 |
0 |
|
|
|
110736 |
3183 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
119 days
| 9 |
|
350.8 |
g |
9.8 |
29.4 |
body weighing method |
0.0 |
0 |
|
|
|
110737 |
3183 |
| GK/MolTac |
blood glucose level |
control condition |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
blood glucose amount |
female |
56 days
| 9 |
|
120.6 |
mg/dl |
1.8 |
5.4 |
blood glucose analysis |
0.0 |
0 |
|
|
|
110263 |
3168 |
| GK/MolTac |
blood hemoglobin A1c level |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
70 days-77 days |
6 |
|
4.75 |
% |
0.06 |
0.14 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103876 |
2864 |
| GK/MolTac |
mean arterial blood pressure |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
arterial blood pressure trait |
male |
112 days
| 8 |
|
104.0 |
mmHg |
5.0 |
14.14 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102961 |
2783 |
| GK/MolTac |
whole body insulin sensitivity index |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
10,000/√(FG x FI) x (Ḡ x Ī) |
1.49 |
null |
0.31 |
0.62 |
oral glucose tolerance test |
7200.0 |
0 |
measured at -5,15,30,45,60,90,120 min |
|
|
103829 |
2864 |
| GK/MolTac |
heart left ventricle end-diastolic posterior wall index |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
heart left ventricle posterior wall thickness |
male |
112 days
| 8 |
|
8.85 |
mm/kg |
0.31 |
0.88 |
echocardiography |
0.0 |
0 |
|
|
|
102992 |
2783 |
| GK/MolTac |
blood dipeptidyl peptidase 4 activity level |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood enzyme amount |
male |
147 days
| 0 |
|
235.0 |
pmol/min |
25.0 |
|
blood enzyme activity assay |
0.0 |
0 |
|
|
|
104009 |
2885 |
| GK/MolTac |
systolic blood pressure |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
arterial blood pressure trait |
male |
112 days
| 8 |
|
127.0 |
mmHg |
5.0 |
14.14 |
vascular transducer tipped catheter |
0.0 |
0 |
|
|
|
102957 |
2783 |
| GK/MolTac |
blood hemoglobin level |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood hemoglobin amount |
male |
70 days-77 days |
7 |
|
14.4 |
g/dl |
0.6 |
1.6 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103853 |
2864 |
| GK/MolTac |
hematocrit |
control condition (between 70 and 77 days) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
70 days-77 days |
6 |
|
42.3 |
% |
3.8 |
9.3 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103864 |
2864 |
| GK/MolTac |
hematocrit |
sodium chloride solution (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
164 days-171 days |
7 |
|
58.1 |
% |
0.6 |
1.6 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103872 |
2864 |
| GK/MolTac |
hematocrit |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
164 days-171 days |
7 |
|
54.8 |
% |
1.85 |
4.9 |
automated hematology analysis |
0.0 |
0 |
|
|
|
103873 |
2864 |
| GK/MolTac |
urine glucose level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
urine glucose amount |
male |
112 days
| 8 |
|
86.0 |
mg/dl |
31.0 |
87.68 |
urine analysis |
0.0 |
0 |
|
|
|
102951 |
2783 |
| GK/MolTac |
blood insulin level |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood insulin amount |
male |
147 days
| 6 |
|
57.65 |
mU/l |
11.47 |
28.1 |
blood insulin analysis |
0.0 |
0 |
|
|
|
103999 |
2885 |
| GK/MolTac |
blood insulin level |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
blood insulin amount |
male |
147 days
| 12 |
|
65.29 |
mU/l |
8.82 |
30.57 |
blood insulin analysis |
0.0 |
0 |
|
|
|
104001 |
2885 |
| GK/MolTac |
plasma NH2-terminal pro-B-type natriuretic peptide level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
blood protein amount |
male |
112 days
| 8 |
|
3416.0 |
ng/l |
585.0 |
1654.63 |
electrochemiluminescence immunoassay |
0.0 |
0 |
|
plasma pro bnp |
|
102933 |
2783 |
| GK/MolTac |
plasma total cholesterol level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
blood cholesterol amount |
male |
112 days
| 8 |
|
96.0 |
mg/dl |
7.0 |
19.8 |
automated plasma total cholesterol analysis |
0.0 |
0 |
|
|
|
102939 |
2783 |
| GK/MolTac |
serum aldosterone level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
blood aldosterone amount |
male |
112 days
| 8 |
|
3.63 |
nmol/l |
0.91 |
2.59 |
radioimmunoassay |
0.0 |
0 |
|
|
|
102945 |
2783 |
| GK/MolTac |
food intake rate |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
eating behavior trait |
female |
240 days
| 11 |
|
15.7 |
g/d |
0.3 |
0.99 |
food intake measuring method |
0.0 |
0 |
|
|
food consumption |
106900 |
3071 |
| GK/MolTac |
systolic blood pressure |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
arterial blood pressure trait |
female |
240 days
| 11 |
|
124.0 |
mmHg |
3.0 |
9.95 |
tail cuff plethysmography |
0.0 |
0 |
10 consecutive measurements |
|
|
106930 |
3071 |
| GK/MolTac |
systolic blood pressure |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
arterial blood pressure trait |
female |
420 days
| 11 |
|
116.0 |
mmHg |
1.7 |
5.64 |
tail cuff plethysmography |
0.0 |
0 |
10 consecutive measurements |
|
|
106931 |
3071 |
| GK/MolTac |
liver wet weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
liver mass |
female |
420 days
| 0 |
|
9.91 |
g |
0.38 |
|
post excision weight measurement |
0.0 |
0 |
|
|
|
106943 |
3071 |
| GK/MolTac |
mean arterial blood pressure |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
arterial blood pressure trait |
male |
112 days
| 0 |
|
118.0 |
mmHg |
1.0 |
|
tail cuff plethysmography |
0.0 |
0 |
|
|
|
108031 |
3109 |
| GK/MolTac |
mean arterial blood pressure |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
arterial blood pressure trait |
male |
154 days
| 0 |
|
127.0 |
mmHg |
4.0 |
|
tail cuff plethysmography |
0.0 |
0 |
|
|
|
108033 |
3109 |
| GK/MolTac |
blood glucose level |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
blood glucose amount |
male |
154 days
| 0 |
|
165.6 |
mg/dl |
34.2 |
|
blood glucose test strip read by electrochemical glucometer |
0.0 |
0 |
|
|
|
108037 |
3109 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
112 days
| 8 |
|
337.1 |
g |
9.3 |
26.3 |
body weighing method |
0.0 |
0 |
|
|
|
110732 |
3183 |
| GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
112 days
| 9 |
|
345.8 |
g |
8.4 |
25.2 |
body weighing method |
0.0 |
0 |
|
|
|
110734 |
3183 |
| GK/MolTac |
serum 8-epi-prostaglandin F2alpha level |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
blood eicosanoid amount |
female |
0 days
| 11 |
|
973.0 |
ng/l |
243.0 |
805.94 |
enzyme immunoassay |
0.0 |
0 |
|
|
blood 8-epi-prostaglandin F2alpha amount |
108087 |
3071 |
| GK/MolTac |
middle cerebral artery outer diameter |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
cerebral artery size trait |
male |
154 days
| 20 |
|
215.0 |
um |
10.0 |
44.72 |
ex vivo light microscopy with inverted microscope |
0.0 |
0 |
with video image analysis |
|
|
109092 |
3109 |
| GK/MolTac |
serum insulin level |
control condition |
Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. |
blood insulin amount |
male |
112 days
| 8 |
|
0.0 |
mg/dl |
0.0 |
0.0 |
enzyme linked immunosorbent assay |
0.0 |
0 |
|
|
|
102943 |
2783 |
| GK/MolTac |
red blood cell count |
rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
erythrocyte quantity |
male |
164 days-171 days |
5 |
|
9.3 |
x 10E6 cells/ul |
0.36 |
0.8 |
automated blood cell counting method |
0.0 |
0 |
|
|
|
103849 |
2864 |
| GK/MolTac |
blood insulin level AUC to blood glucose level AUC ratio |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
AUC ins/glu |
0.0 |
null |
0.0 |
0.0 |
oral glucose tolerance test |
7200.0 |
0 |
measured at -5,15,30,45,60,90,120 min |
|
|
103822 |
2864 |
| GK/MolTac |
Homeostatic Model Assessment of Insulin Resistance |
sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) |
Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. |
blood insulin amount |
male |
122 days-129 days |
4 |
(fasting glucose x fasting insulin)/22.5 |
13.0 |
null |
2.65 |
5.3 |
oral glucose tolerance test |
7200.0 |
0 |
|
|
|
103836 |
2864 |
